
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Interim Results from FDA-Funded Study Reinforces HyBryte’s™ Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat […]